GlassScriptPhysician profile
Silvana Yovanof
NPI 1770561375
$7,615.69
in general payments reported to CMS, 2019-2025
27 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,132 · 2020: $829 · 2021: $931 · 2022: $1,497 · 2023: $1,475 · 2024: $410 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135 · Gift: $59.40 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.47 |
| Gift | $59.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,541.91 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $845.91 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $607.90 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $416.10 | 2021-2025 | Dojolvi |
| Corcept Therapeutics | $409.93 | 2019-2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $360.92 | 2022-2025 | |
| Amarin Pharma, INC. | $336.76 | 2019-2021 | |
| Amgen INC. | $335.48 | 2019-2025 | Repatha |
| Mannkind Corporation | $312.21 | 2023 | Afrezza, V-Go |
| Genentech USA, INC. | $277.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $183.77 | 2019-2023 | |
| Abbott Laboratories | $164.34 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $163.10 | 2022-2023 | |
| Allergan, INC. | $113.89 | 2019 | |
| Stemline Therapeutics INC. | $106.78 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.41 | 2021-2022 | |
| Cequr Corporation | $71.33 | 2024 | Cequr Simplicity |
| Dexcom, INC. | $54.19 | 2021-2023 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $53.01 | 2022-2023 | Mycapssa |
| Esperion Therapeutics, INC. | $48.67 | 2020-2021 | |
| Ibsa Pharma INC. | $24.10 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.91 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $21.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.86 | 2019 | |
| Astellas Pharma US INC | $16.72 | 2023 | Veozah |
| Recordati_rare_diseases_inc. | $14.79 | 2023 | Signifor Lar, Isturisa |
| Insulet Corporation | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvana Yovanof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.